MorphoSys AG sell DirectorDealer_Intensive
Summary
This prediction ended on 27.03.19 with a price of €83.55. The price of MorphoSys AG decreased from the start of the prediction. Compared to the start price this resulted in a performance of -10.74%. DirectorDealer_Intensive has 50% into this predictionMorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| MorphoSys AG | -0.811% | -0.811% | 175.594% | -1.117% |
| iShares Core DAX® | -1.042% | 2.220% | 14.279% | 15.463% |
| iShares Nasdaq 100 | -1.361% | 3.207% | 26.657% | 53.266% |
| iShares Nikkei 225® | -0.044% | -1.680% | 5.941% | 4.271% |
| iShares S&P 500 | -0.480% | 2.165% | 23.067% | 45.283% |
Comments by DirectorDealer_Intensive for this prediction
In the thread Morphosys AG diskutieren
Director's Dealing: Sell
Director's Dealing / Insider Verkauf von Enzelberger, Dr. Markus (Vorstand)
- Handelstag: 24.09.18
- Volumen: 52206 €
- Meldender: Enzelberger, Dr. Markus
sharewise.com analyzes all insider trades. Together with the University of Innsbruck we have developed a trading strategy based on intensive trading. Additional information can be found in DirectorDealer_Intensive's profile.